Peptide

Vesugen

Vesugen (Lys-Glu-Asp, KED)

A synthetic tripeptide targeted at vascular endothelium. Purified from the Ventfort tissue complex. Small Russian trials link it to endothelial function and cognitive endpoints in older adults.

Editor approved

Summary Can Vesugen improve blood vessel health or memory? Show / hide ↓

Vesugen is a laboratory-made chain of three amino acids, the building blocks of proteins, that is intended to support the inner lining of blood vessels. In cell and rat studies, it reduced some signs of aging in blood-vessel cells and reduced artery-wall thickening, but animal and laboratory results do not prove benefits in people. Small, open-label Russian trials involving older adults reported better memory and attention scores and modestly better blood-vessel responses after taking 1 to 2 mg daily for 10 days. These studies had no blinded comparison group and have not been independently repeated. Vesugen is a purified peptide and is not the same as broader tissue-based products that contain several related substances.

What this means for you: Vesugen has an interesting theory but only limited, low-quality human evidence. There is not enough reliable evidence to buy it specifically for memory or blood-vessel health.

weak evidence

Research snapshot No human clinical trials. Khavinson bioregulator peptide.

Updated 2026-08-11

Vesugen is a Russian peptide bioregulator claimed to support vascular health. Evidence is limited to animal studies and Russian-language reports. No independent human trials in Western journals exist. Its cardiovascular claims remain unverified by international standards.

Evidence tierTier 5, Mechanistic hypothesis, minimal human data

Typical doseCommon user protocol: 1 to 2 mg per day orally, morning fasted, 10 to 20 consecutive days, three to four cycles per year.

SafetyNo serious adverse events reported in Russian literature. Long-term independent safety data does not exist.

Categoryresearch peptide (Cytogen)

Last verified2026-08-05

Vesugen is the vascular-directed member of the Khavinson tripeptide family. Its target is endothelial function, and the underlying claim is that KED restores nitric-oxide signaling, reduces endothelial senescence markers, and slows atherosclerotic drift in aged vessels.

Preclinical work reports that KED added to cultured endothelial cells reduces senescence-associated beta-galactosidase staining and restores proliferative capacity in cells from aged donors. In rat models of induced atherosclerosis, oral KED reduced intimal thickening compared with controls. As with the rest of the Khavinson catalog, most of this work is from a single research consortium.

Small Russian human trials in older adults with age-related cognitive and vascular symptoms report that oral KED at 1 to 2 mg per day for 10 days improved memory and attention scores and modestly improved endothelial-dependent vasodilation on ultrasound. These trials are open-label and have not been independently replicated.

Vesugen is the AEDG cousin in the CogniPep formulation, listed as Neurovascular Bioregulator 33B. The rationale is that improving cerebral blood flow via endothelial modulation complements the direct neuronal effects of Cortagen and Pinealon in the same capsule.

A sourcing note that matters: the Cytomax Ventfort contains multiple vascular peptides in a broader complex, dosed at 215 mg per capsule. Vesugen is the isolated KED tripeptide, dosed at 1 to 2 mg oral, or roughly 200 mcg in the US CogniPep format. The two are related but not interchangeable, and users who want the specific KED effect should look for the purified peptide rather than the tissue complex.

Our position: Vesugen sits at Tier 5. Mechanistic story is consistent, human trials are small and unblinded, independent replication is thin.

Related in the encyclopedia

Further reading